<DOC>
	<DOCNO>NCT00566111</DOCNO>
	<brief_summary>We aim study efficacy intravenous ceftriaxone four-week , inpatient , placebo-controlled , double-blind study , augmentation therapy patient bipolar disorder , currently depress , fail respond conventional treatment .</brief_summary>
	<brief_title>Ceftriaxone Management Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>DSMIV diagnosis bipolar disorder Presence current major depressive episode SCID Score 17 great HDRS Failure respond two previous medication trial Capable give voluntary write consent Hypersensitivity penicillin cephalosporin , result anaphylaxis Significant current substance dependence/abuse within 3 month precede trial Significant history intravenous drug abuse Active suicidal ideation Pregnant/lactating mother Significant medical history Patients anticoagulation treatment Patients test positive HIV Hep B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ceftriaxone</keyword>
	<keyword>Acute Antidepressant Effects</keyword>
	<keyword>Glutamatergic System</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Affective Disorders</keyword>
</DOC>